CANNABIS FOR MANAGEMENT OF PAIN: ASSESSMENT OF SAFETY STUDY (COMPASS)
Mark A. Ware, Tongtong Wang, Stan Shapiro, Jean-Paul Collet for the COMPASS study team.
Aline Boulanger MD, John M. Esdaile MD, Allan Gordon MD, Mary Lynch MD, Dwight E. Moulin MD, Colleen O’Connell MD
The Journal of Pain. 2015 Dec; 16 (12): 1233-1242.
The aim of this cohort study with a 1-year follow-up conducted in seven clinical centres was to assess the risk of adverse events related to cannabis when used in the treatment of chronic pain. The results show that medicinal cannabis has a reasonable safety profile and can help with pain management, quality of life and cognitive function.
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
At ANTG, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU. Interested in investing in medicinal cannabis? Read what sets ANTG apart.